Bizarre Patents
Method and apparatus for making a drink hop along a bar or counter
A method for generating a drink which appears to hop from a remote spot on the bar or counter and take one or more leaps, before landing in a patron's glass.
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 8426458 | Hepatitis C Virus inhibitors The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the co... | 04/23/2013 |
| 8426360 | Carbocyclic oxime hepatitis C virus serine protease inhibitors The present invention discloses compounds of formula I, II, or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3... | 04/23/2013 |
| 8420686 | Linked diimidazole antivirals The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the co... | 04/16/2013 |
| 8420596 | Macrocyclic hepatitis C serine protease inhibitors The present invention relates to novel macrocyclic compounds and methods of treating a hepatitis C infection in a subject in need of such therapy with said macrocyclic compounds. The present invention further relates to pharmaceutical compositions comprising the com... | 04/16/2013 |
| 8383785 | Anti-bacterial activity of 9-hydroxy derivatives of 6,11-bicyclolides The present invention discloses compounds of formula (I) or pharmaceutically acceptable salts, esters, or prodrugs thereof: which exhibit superior antibacterial properties, particularly against Haemophilus influenzae... | 02/26/2013 |
| 8383583 | Macrocyclic, pyridazinone-containing hepatitis C serine protease inhibitors The present invention relates to compounds of Formula I, II, or III, or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus ... | 02/26/2013 |
| 8377872 | Cyclic P3 tripeptide hepatitis C serine protease inhibitors The present invention relates to compounds of Formula I, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS... | 02/19/2013 |
| 8372802 | Fluorinated macrocyclic compounds as hepatitis C virus inhibitors The present invention discloses compounds of formula I or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A... | 02/12/2013 |
| 8367618 | Cyclosporin analogues for preventing or treating hepatitis C infection The present invention relates to cyclosporin analogues having antiviral activity against HCV and useful in the treatment of HCV infections. More particularly, the invention relates to novel cyclosporin analogue compounds, compositions containing such compounds and m... | 02/05/2013 |
| 8367053 | Cyclosporin analogues The present invention provides novel cyclosporin analogue compounds, pharmaceutical compositions comprising these compounds and methods of using these compounds for the treatment of disorders and diseases, including immune disorders, inflammatory disorders and viral... | 02/05/2013 |
| 8361958 | Oximyl HCV serine protease inhibitors The present invention discloses compounds of formula I or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A... | 01/29/2013 |
| 8354383 | 6,11-bridged biaryl macrolides The present invention discloses compounds of formula I, II or X, or pharmaceutically acceptable salts, esters, or prodrugs thereof: which exhibit antibacterial properties. The present invention further relates to pharmaceut... | 01/15/2013 |
| 8349312 | Proline substituted cyclosporin analogues The present invention provides novel proline substituted cyclosporinanalogue compounds, pharmaceutical compositions comprising these compounds and methods of using these compounds for the treatment of disorders and diseases, including immune disorders, inflammatory ... | 01/08/2013 |
| 8324155 | Quinoxaline-containing compounds as hepatitis C virus inhibitors The present invention discloses compounds of formula I and II or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) N... | 12/04/2012 |
| 8314135 | Linked dibenzimidazole antivirals The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the co... | 11/20/2012 |
| 8304385 | Macrocyclic tetrazolyl hepatitis C serine protease inhibitors The present invention relates to compounds of Formula I, II, III or IV, or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit serine protease activity, particularly the activity of hepatitis C vir... | 11/06/2012 |
| 8283309 | Bridged carbocyclic oxime hepatitis C virus serine protease inhibitors The present invention discloses compounds of formula I, or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4... | 10/09/2012 |
| 8273720 | 6,11-bicyclolides: bridged biaryl macrolide derivatives The present invention discloses compounds of formula I, or pharmaceutically acceptable salts, esters, or prodrugs thereof: which exhibit antibacterial properties. The present invention further relates to pharmaceutical comp... | 09/25/2012 |
| 8273709 | Triazole-containing macrocyclic HCV serine protease inhibitors The present invention discloses compounds of formula I, II and III or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (H... | 09/25/2012 |
| 8268777 | Oximyl macrocyclic derivatives The present invention relates to compounds of Formula I, or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS... | 09/18/2012 |
| 8268776 | Macrocylic oximyl hepatitis C protease inhibitors The present invention discloses compounds of formula I, or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4... | 09/18/2012 |
| 8263549 | C5-substituted, proline-derived, macrocyclic hepatitis C serine protease inhibitors The present invention relates to compounds of Formula I or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4... | 09/11/2012 |
| 8242156 | Linked dibenzimidazole derivatives The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the co... | 08/14/2012 |
| 8236807 | Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors The present invention relates to compounds of Formula I or II, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) ... | 08/07/2012 |
| 8222203 | Macrocyclic oximyl hepatitis C serine protease inhibitors The present invention relates to compounds of Formula I, or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS... | 07/17/2012 |
| 8221737 | Hepatitis C virus inhibitors The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the co... | 07/17/2012 |
| 8211891 | Difluoromethyl-containing macrocyclic compounds as hepatitis C virus inhibitors The present invention discloses compounds of formula I or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A... | 07/03/2012 |
| 8193346 | Process for making macrocyclic oximyl hepatitis C protease inhibitors The present invention relates to a process for the preparation of macrocyclic compounds that are useful as hepatitis C virus (HCV) protease inhibitor compounds. ... | 06/05/2012 |
| 8188132 | Linked dibenzimidazole derivatives The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the co... | 05/29/2012 |
| 8178531 | Antiviral agents The present invention relates to antiviral compounds of formula (I), compositions containing these compounds, processes for their preparation, intermediates in their synthesis, and their use as therapeutics for prevention o... | 05/15/2012 |
| 8163707 | 4′-allene-substituted nucleoside derivatives The present invention discloses compounds of formula (I), or its β-L enantiomer, or a pharmaceutically acceptable salt, ester, stereoisomer, tautomer, solvate, prodrug, or combination thereof: which inhibit, preventing or ... | 04/24/2012 |
| 8124584 | Macrocyclic hepatitis C serine protease inhibitors The present invention relates to compounds of Formula I, II or III, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: wherein W is a substituted or unsubstituted heterocyclic ring s... | 02/28/2012 |
| 8101643 | Benzimidazole derivatives The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the co... | 01/24/2012 |
| 8101567 | Heteroaryl-containing tripeptide HCV serine protease inhibitors The present invention relates to compounds of Formula I, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: which inhibit serine protease activity, particularly the activity of hepatitis c virus (HCV) NS3-NS... | 01/24/2012 |
| 8030307 | Bicyclic, C5-substituted proline derivatives as inhibitors of the hepatitis C virus NS3 protease The present invention relates to compounds of Formula I or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4... | 10/04/2011 |
| RE42375 | Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors The present invention relates to compounds of Formula I or II, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS... | 05/17/2011 |
| 7919627 | Processes for the preparation of hydroxylamines The present invention relates generally to novel methods for the synthesis of O-(6-pyrazol-1-yl-pyridin-3-ylmethyl)-hydroxylamine which is an essential reagent in the synthesis of one of the bridged erythromycin derivatives and their respective pharmaceutically acce... | 04/05/2011 |
| 7910587 | Quinoxalinyl dipeptide hepatitis C virus inhibitors The present invention relates to compounds of Formula I, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS... | 03/22/2011 |
| 7910558 | Bridged macrocyclic compounds and processes for the preparation thereof The present invention provides a method for preparing bridged macrocyclic compounds comprising the step of reacting a macrocyclic compound characterized by having at least two nucleophilic moieties with a bifunctional bridging reagent optionally in the presence of a... | 03/22/2011 |
| 7906513 | Hydrazide-containing hepatitis C serine protease inhibitors The present invention relates to novel hydrazide-containing compounds of Formula I or Formula II, including pharmaceutically acceptable salts, esters, or prodrugs thereof which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS... | 03/15/2011 |
